Clinical trial NCT04914117: A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
Official title: Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Unresectable Solid Tumor
Metastatic Solid Tumor
Locally Advanced Solid Tumor
Lead sponsor: RemeGen Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2021-06-04
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients with Locally Advanced Unresectable/Metastatic Solid Tumours to determine the safety and tolerability of RC118, including the maximum tolerated dose (MTD)/maximum administered dose (MAD), and to define the recommended Phase II dose (RP2D).

Detailed description: This is an open-label, Phase 1, FIH, study consisting of dose-escalation (Part A) and dose confirmation (Part B) in Australia. This trial is to evaluate the safety, tolerability (MTD/MAD), PK, immunogenicity of RC118, and further determine the RP2D. In addition, the preliminary anti-tumour efficacy of RC118 as single agent will be assessed.

Eligibility criteria: Inclusion Criteria:

1. Patients must be able to provide documented voluntary informed consent.
2. Male or female patient ≥ 18 years and ≤ 75 years.
3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0 or 1.
4. The expected survival period exceeds 12 weeks.
5. At least one target lesion that can be measured per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
6. Histologically documented, incurable, unresectable locally advanced or metastatic tumours that are intolerable or refractory to standard therapies.
7. Patients agree to provide pre-treatment archived /biopsy tumour samples for retrospective Claudin 18.2 test. Archival tumour tissue should be from the most recent timepoint before entering the trial. In addition, archived samples obtained out of the screening are acceptable if it is discussed and approved by the Investigator and Sponsor in advance. Only when archived samples cannot be obtained, the biopsy will be considered at screening. Fresh tumour biopsies will NOT be considered if significant risk procedures are required with the discretion of Investigator.
8. Adequate bone marrow, liver, and renal function defined as: absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet ≥ 100 × 109/L, haemoglobin ≥ 90 g/L, serum total bilirubin ≤ 1.5 × upper limit of normal (ULN), ALT, AST or ALP ≤ 2.5 × ULN (≤ 5 × ULN when there is known liver metastasis), serum creatinine ≤ 1.5 × ULN, INR ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN.
9. Willingness to avoid pregnancy or fathering children based on the criteria below:

   * Female patients of childbearing potential and male patients with partners of childbearing potential treated with RC118, must agree to use a highly effective form(s) of contraception during study and within 6 months after the last dose. Those methods include but not limited to combined (oestrogen and progestogen containing) hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion or vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.
   * Females of non-childbearing potential (e.g., surgically sterile with a hysterectomy and/or bilateral oophorectomy or chemically sterile or ≥ 12 months of amenorrhea in the absence of chemotherapy, anti-oestrogens, or ovarian suppression). Those females do not need to undergo pregnancy test.

Exclusion Criteria:

1. Women who are pregnant or breastfeeding.
2. Diagnosed active hepatitis B infection (defined as positive of hepatitis B surface Ag and hepatitis B DNA≥500IU/ml), active hepatitis C infection (defined as presence of hepatitis C RNA), and human immunodeficiency virus infection (defined as positive HIV test) during the screening period.
3. Received vaccines within 4 weeks prior to administration or plan on receiving any vaccine during the study.
4. Subjects with a history of other acquired/congenital immunodeficiency diseases or organ transplantation.
5. Patients have history of targeted therapy of Claudins, or participated in other clinical trials and received investigational product within 4 weeks before the first administration of study drug.
6. Allergic constitution or allergic to known research drug active ingredients or excipient.
7. Patients who are under the treatment of anticoagulant drugs (e.g., warfarin, apixaban, and heparin). Patients using prophylactic doses of heparin (e.g., LMWH) is eligible in the study.
8. Patients undergoing any anti-tumour therapy, including surgery, chemotherapy, radiotherapy and biological therapy, within 4 weeks prior to the first administration of study drug, or palliative radiotherapy for bone/other solitary metastases within 2 weeks prior to the first administration of study drug.
9. Previous adverse reactions resulting from previous anti-tumour therapies, which have not returned to Grade 0 or 1 according to NCI-CTCAE v5.0 (except alopecia) at screening.
10. There are clinical symptoms of fluid in the third space (e.g., large amounts of pleural fluid or ascites) that cannot be controlled by drainage or other therapies.
11. A clinically significant active infection judged by the investigator.
12. Comorbidities that may seriously endanger the patient's safety or affect the completion of the study, such as gastrointestinal bleeding (within 4 weeks prior to the screening period), peptic ulcer, intestinal obstruction, intestinal paralysis, interstitial pneumonia, pulmonary fibrosis, kidney failure, and uncontrolled diabetes.
13. QTc interval \> 480 ms in both male and female (based on the mean value of the triplicate screening ECGs); family or personal history of long/short QT syndrome, History of ventricular arrhythmia deemed clinically significant by the investigator, or currently receiving antiarrhythmic drug treatment, or implantation of arrhythmia defibrillation device.
14. History of myocardial infarction within 6 months prior to the screening period, severe or unstable angina pectoris, coronary or peripheral artery bypass grafting, heart failure ≥ 3 (New York Heart Association), or uncontrolled hypertension.
15. Patients with known current alcohol dependence or drug abuse.
16. Patients with a long-term history of systemic steroid therapy. Patients with short-term (≤ 7 days) use and drug withdrawal \> 2 weeks are eligible.
17. History or presence of uncontrolled primary brain tumours (e.g., leptomeningeal carcinomatosis) or metastatic brain tumours, unless considered stable by the Investigator and local therapy was completed.
18. History or presence of Grade ≥ 2 peripheral neuropathy.
19. History or presence of uncontrolled mental illness at the discretion of the Investigator, which may place the participant at increased risk of safety/tolerability issues.
20. The patient is, in the opinion of the investigator, expected to be non-compliant with critical trial procedures and is not willing or able to adhere to the trial requirements in the future.
21. Patients who are not appropriate for this clinical trial at the discretion of the investigator.

Primary outcomes:
measure: MTD/MAD based on number of dose-limiting toxicities (DLTs)
timeFrame: Up to 18 months
measure: Determine Recommended Phase 2 Dose (RP2D)
timeFrame: Up to 18 months
measure: Adverse Events
timeFrame: Up to 18 months
Secondary outcomes:
measure: Object Response Rate (ORR)
timeFrame: Up to 18 months
measure: Progression Free Survival (PFS)
timeFrame: Up to 18 months
measure: Disease Control Rate (DCR)
timeFrame: Up to 18 months
measure: Duration of response (DOR)
timeFrame: Up to 18 months
measure: Immunogenicity
timeFrame: Up to 18 months
measure: Maximum Plasma Concentration [Cmax]
timeFrame: Up to 18 months
measure: Area under the plasma concentration [AUC]
timeFrame: Up to 18 months
measure: Tmax
timeFrame: Up to 18 months
Other outcomes:
measure: CLDN18.2 expression
timeFrame: Up to 18 months
Locations:
city: Macquarie Park
country: Australia
facility: Remegen Site #12
state: New South Wales
city: Bedford Park
country: Australia
facility: Remegen Site #14
state: South Australia
city: Frankston
country: Australia
facility: Remegen Site #13
state: Victoria
city: Malvern
country: Australia
facility: Remegen Site #11
state: Victoria
Study officials:
References: